Open AccessA Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication
Author(s) -
SengKee Chuah,
ChihMing Liang,
ChenHsiang Lee,
Shue-Shian Chiou,
YiChun Chiu,
MingLuen Hu,
KengLiang Wu,
LungSheng Lu,
YehPin Chou,
KuoChin Chang,
Chia-Hua Kuo,
ChungMou Kuo,
Tsung–Hui Hu,
WeiChen Tai,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChihMing Liang,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
ChenHsiang Lee,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
Shue-Shian Chiou,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
YiChun Chiu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
MingLuen Hu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
KengLiang Wu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
LungSheng Lu,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
YehPin Chou,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
KuoChin Chang,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
Chia-Hua Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
ChungMou Kuo,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
Tsung–Hui Hu,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai,
WeiChen Tai
Publication year - 2016
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000003586
Subject(s) - levofloxacin , medicine , esomeprazole , amoxicillin , metronidazole , helicobacter pylori , clarithromycin , regimen , gastroenterology , randomized controlled trial , proton pump inhibitor , intention to treat analysis , surgery , antibiotics , microbiology and biotechnology , biology
Supplemental Digital Content is available in the text